Arcellx [ACLX] vs Praxis Precision [PRAX] Detailed Stock Comparison

Arcellx Inc.

NASDAQ
Loading...

Praxis Precision Medicines Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 17 vital metrics comparison: Arcellx Inc. wins in 6 metrics, Praxis Precision Medicines Inc. wins in 7 metrics, with 1 ties. Praxis Precision Medicines Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Arcellx Inc. Praxis Precision Medicines Inc. Better
Price-to-Book Ratio 16.56 9.46 Praxis Precision Medicines Inc.
Debt-to-Equity Ratio 12.90 0.01 Praxis Precision Medicines Inc.
PEG Ratio -66.41 -38.31 Praxis Precision Medicines Inc.
EV/EBITDA -25.69 -26.32 Arcellx Inc.
Profit Margin (TTM) 0.00% 0.00% Tie
Operating Margin (TTM) -3,850.24% 0.00% Praxis Precision Medicines Inc.
Return on Equity -53.42% -45.83% Praxis Precision Medicines Inc.
Return on Assets (TTM) -24.05% -28.69% Arcellx Inc.
Free Cash Flow (TTM) $-212.59M $-249.12M Arcellx Inc.
1-Year Return 95.76% 501.76% Praxis Precision Medicines Inc.
Price-to-Sales Ratio (TTM) 301.85 N/A N/A
Enterprise Value $6.33B $8.58B Praxis Precision Medicines Inc.
EV/Revenue Ratio 284.02 N/A N/A
Revenue per Share (TTM) $0 N/A N/A
Earnings per Share (Diluted) $-4.07 $-13.48 Arcellx Inc.
Beta (Stock Volatility) 0.25 2.97 Arcellx Inc.
Short % of Float 5.27% 14.21% Arcellx Inc.

Arcellx Inc. vs Praxis Precision Medicines Inc. Stock Performance Analysis

Loading Price Chart...

ACLX
PRAX

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Arcellx Inc.0.00%0.00%0.06%63.92%27.37%81.67%
Praxis Precision Medicines Inc.-0.77%4.46%-22.78%-13.27%-4.29%-7.63%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Arcellx Inc.95.76%177.88%584.94%584.94%584.94%584.94%
Praxis Precision Medicines Inc.501.76%1,560.93%-17.42%-36.07%-36.07%-36.07%

Performance & Financial Health Analysis: Arcellx Inc. vs Praxis Precision Medicines Inc.

MetricACLXPRAX
Market Information
Market Cap i$6.73B$9.60B
Market Cap CategoryMid capMid cap
10 Day Avg. Volume i616,459391,453
90 Day Avg. Volume i1,025,300416,321
Last Close$115.07$264.54
52 Week Range$56.58 - $115.13$37.19 - $366.52
% from 52W High-0.05%-27.82%
All-Time High$115.13 (Apr 17, 2026)$914.27 (Jan 04, 2021)
% from All-Time High-0.05%-71.07%
Growth Metrics
Quarterly Revenue Growth-0.89%N/A
Quarterly Earnings Growth-0.89%-1.00%
Financial Health
Profit Margin (TTM) i0.00%0.00%
Operating Margin (TTM) i-38.50%0.00%
Return on Equity (TTM) i-0.53%-0.46%
Debt to Equity (MRQ) i12.900.01
Cash & Liquidity
Book Value per Share (MRQ)$6.95$34.85
Cash per Share (MRQ)$7.70$21.52
Operating Cash Flow (TTM) i$-210,258,000$-249,068,000
Levered Free Cash Flow (TTM) i$-97,093,872$-146,253,744
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Arcellx Inc. vs Praxis Precision Medicines Inc.

MetricACLX (Apr 26, 2026)PRAX (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) iN/AN/A
Forward P/E i-66.41-38.31
PEG Ratio i-66.41-38.31
Price to Sales (TTM) i301.85N/A
Price to Book (MRQ) i16.569.46
Market Capitalization
Market Capitalization i$6.73B$9.60B
Enterprise Value i$6.33B$8.58B
Enterprise Value Metrics
Enterprise to Revenue i284.02N/A
Enterprise to EBITDA i-25.69-26.32
Risk & Other Metrics
Beta i0.252.97
Book Value per Share (MRQ) i$6.95$34.85

Financial Statements Comparison: Arcellx Inc. vs Praxis Precision Medicines Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricACLX (2025)PRAX (2025)
Revenue/Sales i22.29M0
Cost of Goods Sold iN/AN/A
COGS % of Revenue i0.0%-
Gross Profit iN/AN/A
Gross Margin i0.0%-
Research & Development i157.61M267.12M
Operating Income (EBIT) i-253.08M-326.20M
Operating Margin i-1,135.6%-
EBITDA i-222.19M-326.06M
EBITDA Margin i-997.0%-
Pre-Tax Income i-228.87M-303.27M
Pre-Tax Income % of Revenue i-1,026.9%-
Income Tax i69,000N/A
Income Tax % of Revenue i0.3%-
Net Income (Profit) i-228.93M-303.27M
Profit Margin i-1,027.3%-

Balance Sheet & Liquidity Metrics

MetricACLX (2025)PRAX (2025)
Cash & Equivalents i80.26M357.33M
Total Current Assets i462.18M610.91M
Total Current Assets % of Revenue i2,073.9%-
Total Current Liabilities i104.20M59.77M
Total Current Liabilities % of Revenue i467.6%-
Long-Term Debt i44.34M0
Long-Term Debt % of Revenue i199.0%-
Total Shareholders Equity i402.35M878.14M
Retained Earnings i-725.76M-1.14B
Retained Earnings % of Revenue i-3,256.6%-
Property, Plant & Equipment i42.63M415,000

Cash Flow Statement Comparison

MetricACLX (2025)PRAX (2025)
Operating Cash Flow i-178.25M-257.32M
Operating Cash Flow % of Revenue i-799.8%-
Capital Expenditures i-2.33M-56,000
Free Cash Flow i-212.59M-249.12M
FCF Margin i-953.9%-
Debt Repayment i-230,000N/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricACLXPRAX
Shares Short i2.27M3.95M
Short Ratio i1.629.07
Short % of Float i5.27%14.21%
Shares Outstanding i57.93M25.20M
Float Shares i42.25M25.78M
% Held by Insiders i12.92%0.40%
% Held by Institutions i90.08%106.12%
% Held by Public i-3.00%-6.52%

Dividend Analysis & Yield Comparison: Arcellx Inc. vs Praxis Precision Medicines Inc.

MetricACLXPRAX
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A